HER2 genetic heterogeneity in breast carcinoma

Christian Ohlschlegel; Katharina Zahel; Doris Kradolfer; Margreth Hell; Wolfram Jochum

首页> 外文期刊>Journal of Clinical Pathology >HER2 genetic heterogeneity in breast carcinoma

【24h】

HER2 genetic heterogeneity in breast carcinoma

机译：乳腺癌中HER2遗传异质性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims To determine the frequency of HER2 genetic heterogeneity according to the recent American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) definition (2009) in invasive breast carcinoma, and to identify clinicopathological features that characterise breast carcinomas with HEH2 genetic heterogeneity.

机译：目的根据侵入性乳腺癌的最新美国临床肿瘤学会（ASCO）和美国病理学家学会（CAP）定义（2009）确定HER2遗传异质性的频率，并鉴定具有HEH2遗传学特征的乳腺癌的临床病理特征异质性。

著录项

来源
《Journal of Clinical Pathology》 |2011年第12期|p.1112-1116|共5页
作者
Christian Ohlschlegel; Katharina Zahel; Doris Kradolfer; Margreth Hell; Wolfram Jochum;
展开▼
作者单位

Institute of Pathology,Kantonsspital St Gallen,St Gallen, Switzerland;

Institute of Pathology,Kantonsspital St Gallen,St Gallen, Switzerland;

Institute of Pathology,Kantonsspital St Gallen,St Gallen, Switzerland;

Institute of Pathology,Kantonsspital St Gallen,St Gallen, Switzerland;

Institute of Pathology,Kantonsspital St Gallen,St Gallen, Switzerland;

展开▼
收录信息美国《科学引文索引》(SCI);美国《化学文摘》(CA);
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits [J] . Pekar Gyula, Kasselaki Ionna, Pekar-Lukacs Agnes, Histopathology: Official Journal of the British Division of the International Academy of Pathology . 2019,第2期

机译：Equirocal（HER2 IHC 2+）乳腺癌：基因蛋白质测定试验揭示了遗传异质性，个体细胞扩增状态和潜在治疗效益之间的关联
2. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma [J] . Yanjun Hou, Hiroaki Nitta, Lai Wei, Breast cancer research and treatment. . 2017,第2期

机译：Her2肿瘤内异质性与对HER2阳性乳腺癌的抗HER2 Neoadjuvant化疗的不完全反应独立相关
3. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2|[sol]|neu (basal-like breast carcinomas) [J] . Enrique Lerma, Gloria Peiro, Teresa Ramón, Modern Pathology . 2007,第11期

机译：雌激素受体，孕激素受体和Her2 | [sol] | neu阴性的乳腺癌的免疫组织化学异质性（基底样乳腺癌）
4. Immunohistochemistry applications in breast carcinoma: The Hypoxia Inducible Factor lα, Estrogen Receptor, Progesterone Receptor and HER2 expression before and after neoadjuvant chemotherapy [C] . Zuofeng Zhang, Yunai Liang, Chunhua Zhang, Technical Congress on Resources, Environment and Engineering . 2016

机译：免疫组织化学在乳腺癌中的应用：缺氧诱导因子Lα，雌激素受体，孕酮受体和Neoadjuvant化疗前后和Her2表达
5. HER2Delta16: a tumor-specific oncogene that drives tumorigenesis and trastuzumab resistance in HER2+ breast cancer. [D] . Huynh, Felicia C. 2015

机译：HER2Delta16：一种肿瘤特异性癌基因，可驱动HER2 +乳腺癌的肿瘤发生和曲妥珠单抗。
6. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification [O] . Charlotte KY Ng, Luciano G Martelotto, Arnaud Gauthier, 2015

机译：异种HER2基因扩增在乳腺癌中的肿瘤内遗传异质性和替代性驱动基因的改变
7. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) [O] . Enrique Lerma, Gloria Peiro, Teresa Ramón, 2007

机译：乳腺癌，孕激素受体和Her2 / Neu（基类乳腺癌）的免疫组化异质性

HER2 genetic heterogeneity in breast carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅